Feed CASI
CA

CASI Pharmaceuticals, Inc. CASI · NASDAQ

$0.15 +3.08% (+$0.00)

Summary

53 / 100 · Bulios Score

What speaks for it

  • Revenue grew by 119% a year over the last 3 years.
  • It holds more cash than debt: $84.2M against $1.50M.

What to watch

  • The company made a loss over the last 12 months.
  • It missed profit estimates 6 times in the last 8 quarters.
  • It passes only 3 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

  • Analyst estimate

Revenue grew by 47% a year over 5 years. Over the last 3 years it grew by 119% a year.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Yes

It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

This revenue breakdown is on the way.

By region

This revenue breakdown is on the way.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.